A First-in-human, Randomized, Double Blind, Placebo Controlled, Single-centre Study to Assess the Safety and Tolerability of HAL-MPE1 in Patients With Peanut Allergy
Phase of Trial: Phase I
Latest Information Update: 06 Mar 2017
Price : $35 *
At a glance
- Drugs HAL MPE1 (Primary)
- Indications Peanut hypersensitivity
- Focus Adverse reactions; First in man
- Sponsors HAL Allergy
- 06 Mar 2017 Results presented at the 2017 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
- 09 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 15 Jan 2015 Planned End Date changed from 1 Feb 2015 to 1 Jun 2015 as reported by ClinicalTrials.gov.